Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 05, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 828,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,337.49 pence per share.
- Treasury Shares Held: 228,147,678 shares following the transaction.
- Shares in Issue: 5,762,926,449 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on December 05, 2006, pursuant to shareholder authority granted at the Annual General Meeting on May 17, 2006. The filing text does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 828,000 shares purchased at 1,337.49 pence per share.
- Confirm the updated total number of shares in issue and treasury holdings as of December 05, 2006.
- Review the remaining authorization for share buybacks under the mandate approved on May 17, 2006.